Let's Talk Risk!
Let's Talk Risk!
  • 262
  • 620 595
LTR 68: Tips for making customer-focused decisions
“Before making a decision, we have to look at the issues end-to-end. We have to consider how our actions will impact the customer.”
In this Let’s Talk Risk! conversation (naveenagarwalphd.substack.com/podcast) , Rajesh Kathuria emphasizes the need to consider the full impact of our actions on safety of customers and users and quality of performance. As an example, when working at the component level, we should consider the impact of any changes at the system level and how it could affect the safety of end user or the patient.
Rajesh advises industry colleagues to take the emotions out, and rely on data as much as possible. If you don’t have good quality data, your first decision could be to take the time and gather more information, especially when the potential consequences of failure could be catastrophic. He also recommends to consider diverse viewpoints from a cross-functional experienced team as part of the decision making process.
Listen to this Let’s Talk Risk! conversation with Rajesh Kathuria which also includes an open discussion with a live audience. Jump to a section of interest using these timestamps.
00:02:10 Introduction
00:05:42 Considering risks in decision making
00:08:25 An example of missing long-term factors in decision making
00:10:09 Taking a systems approach to finding solutions
00:12:13 An example of a difficult decision to delay a project to ensure safety
00:14:30 Difficult decisions require courage to do the right thing
00:16:30 Leadership advice for QA/RA professionals
00:17:50 Audience Q&A and open discussion
00:35:50 Closing comments and key takeaways
If you enjoyed this podcast, consider subscribing to the Let’s Talk Risk! newsletter (naveenagarwalphd.substack.com/subscribe) .
Suggested links:
LTR podcast: Understanding risk-based thinking (naveenagarwalphd.substack.com/p/understanding-risk-based-thinking)
LTR podcast: Getting comfortable with a probabilistic way of thinking about risk (naveenagarwalphd.substack.com/p/risk-management-needs-probabilistic-thinking)
About Rajesh Kathuria
Rajesh Kathuria (www.linkedin.com/in/rajesh-kathuria-599546/) is a currently the Owner and Director at KMS Solutions, B.V, providing strategic consulting services in Quality and Regulatory for medical device companies. He is a seasoned leader with over 20 years of industry experience in senior leadership positions. He holds a Bachelors degree in Mechanical Engineering and Graduate degree in Management with specialization in International Marketing and Finance. He is also a certified ISO 13485 lead auditor and has extensive experience of auditing/working in various geographies and different global regulations.
Let’s Talk Risk! with Dr. Naveen Agarwal is a weekly live audio event on LinkedIn, where we talk about risk management related topics in a casual, informal way. Join us at 11:00 am EST every Friday on LinkedIn.
Disclaimer
Information and insights presented in this podcast are for educational purposes only. Views expressed by all speakers are their own and do not reflect those of their respective organizations.
This is a public episode. If you’d like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe (naveenagarwalphd.substack.com/subscribe?CTA_2)
āļĄāļļāļĄāļĄāļ­āļ‡: 10

āļ§āļĩāļ”āļĩāđ‚āļ­

LTR 67: 3 pillars for defining your IVD risk management strategy
āļĄāļļāļĄāļĄāļ­āļ‡ 2016 āļŠāļąāđˆāļ§āđ‚āļĄāļ‡āļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
“There are 3 pillars I consider essential to defining a strategy for IVD risk management. What is the system definition, who are the user groups, and what is the level of novelty?” In this Let’s Talk Risk! conversation (naveenagarwalphd.substack.com/podcast) , Claudia Campbell-Matland highlights the broad range of in-vitro diagnostic devices (IVD), which requires a strategic approach to their d...
LTR 66: Understanding human factors aspect of augmented reality applications in medical devices
āļĄāļļāļĄāļĄāļ­āļ‡ 1814 āļ§āļąāļ™āļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
“To be able to see a virtual image over the real world - that augmented reality is - is a mind blowing, very different experience.” In this Let’s Talk Risk! conversation (naveenagarwalphd.substack.com/podcast) , Phil Deming shares some of the unique human factors engineering challenges for an augmented reality (AR) technology for 3D visualization of human anatomy in real time during a medical p...
LTR 65: Demystifying risk-based approach vs. risk management
āļĄāļļāļĄāļĄāļ­āļ‡ 3921 āļ§āļąāļ™āļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
“It’s too often confused with risk management itself. Part of the risk-based approach is just the mindset, the thinking about risk, and then deciding ‘so what should we do?’, the answer to which might be a formal risk management.” In this Let’s Talk Risk! conversation (naveenagarwalphd.substack.com/podcast) , Steve Gompertz clarifies a subtle difference between a risk-based approach and formal ...
LTR 64: Opportunities and challenges to leverage PCCP for speed to market
āļĄāļļāļĄāļĄāļ­āļ‡ 1228 āļ§āļąāļ™āļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
This is a free preview of a paid episode. To hear more, visit naveenagarwalphd.substack.com (naveenagarwalphd.substack.com?CTA_7) Summary “PCCP is a great tool for your regulatory strategy but it is not for every company or for every change”. PCCP (Predetermined Change Control Plan) is a new regulatory scheme that allows device manufacturers to implement post-market changes without requiring pr...
LTR 63: A lawyer's perspective on the QMSR transition
āļĄāļļāļĄāļĄāļ­āļ‡ 13āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
“Don’t be comfortable saying, ‘Oh I follow the ISO (13485) to the letter’; it doesn’t matter. You have to comply with 21 CFR 820.” In this Let’s Talk Risk! conversation (naveenagarwalphd.substack.com/podcast) , Neil Di Spirito, helps us understand the full legal context behind the Quality Management System Regulation (QMSR), the amended version of 21 CFR 820 that will go into effect in February...
LTR 62: Overcoming barriers to cross-functional communication and collaboration
āļĄāļļāļĄāļĄāļ­āļ‡ 22āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
“There is a growing awareness that if you bring in Regulatory at the beginning of designing a product, you will end up with a more robust product. In this Let’s Talk Risk! conversation (naveenagarwalphd.substack.com/podcast) , Christine Zomorodian highlights some of the barriers that have traditionally hindered good communication and collaboration between QA/RA and Engineering functions in MedT...
LTR 61: Treat human factors as a driver of customer satisfaction, not a check-the-box activity
āļĄāļļāļĄāļĄāļ­āļ‡ 12āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
“There is a tendency for human factors to be very closely tied to regulatory requirements and nothing else, but human factors as a core discipline is about user-centered design.” In this Let’s Talk Risk! conversation (naveenagarwalphd.substack.com/podcast) , Korey Johnson highlights how the current practice of human factors engineering in the medical device industry is mainly driven by regulato...
Medical Device Software Risk Management - Challenges and Tips
āļĄāļļāļĄāļĄāļ­āļ‡ 56āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
ðŸ’ĨSoftware failures can lead to harm but they are not predictable! ➡ïļIn this brief clip from a Let's Talk Risk! webinar, I discuss some of the challenges in software risk management using a case study of a recent recall. ✅Listen to the full recording of the webinar here ➡ïļnaveenagarwalphd.substack.com/p/tips-for-medical-device-software-risk-management In this hour long webinar, we discuss the fo...
LTR 60: Defining state of the art can be challenging; here are a few tips.
āļĄāļļāļĄāļĄāļ­āļ‡ 25āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
“There is a very strong push (in the EU) to look at threshold values and acceptance criteria in the clinical evaluation, and these acceptance criteria for benefit risk have to be based on the state of the art.” State of the art (SoTA) is a very important topic in the medical device industry, because it is directly connected to risk acceptability and benefit-risk evaluation, which in turn, is di...
LTR 59: FDA's pre-sub program and how it can accelerate medical device innovation
āļĄāļļāļĄāļĄāļ­āļ‡ 302 āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
“You can get a lot of valuable insights from the FDA on what your regulatory pathway is when it comes to risk, and how that impacts not only the risk of the product but how you set up your quality systems and what you need to implement in the long run. ” In this Let’s Talk Risk! conversation (naveenagarwalphd.substack.com/podcast) , Amit Guruprasad shares how small medical device manufacturers ...
LTR 58: Tips for clinicians transitioning into a medical safety role in MedTech
āļĄāļļāļĄāļĄāļ­āļ‡ 172 āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
LTR 58: Tips for clinicians transitioning into a medical safety role in MedTech
Understanding terminology - SaMD, AI, ML
āļĄāļļāļĄāļĄāļ­āļ‡ 232 āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
Understanding terminology - SaMD, AI, ML
LTR 57: It's time to focus on supply chain resiliency not just supplier management
āļĄāļļāļĄāļĄāļ­āļ‡ 342 āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
LTR 57: It's time to focus on supply chain resiliency not just supplier management
LTR 56: How to communicate effectively with senior management
āļĄāļļāļĄāļĄāļ­āļ‡ 352 āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
LTR 56: How to communicate effectively with senior management
Webinar: How to set up post-market surveillance for your medical device
āļĄāļļāļĄāļĄāļ­āļ‡ 823 āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
Webinar: How to set up post-market surveillance for your medical device
LTR 54: Start your risk analysis by first defining the intended use
āļĄāļļāļĄāļĄāļ­āļ‡ 593 āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
LTR 54: Start your risk analysis by first defining the intended use
LTR 53: Three big trends to watch in MedTech
āļĄāļļāļĄāļĄāļ­āļ‡ 483 āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
LTR 53: Three big trends to watch in MedTech
LTR 52: The key to success as a risk practitioner in the medical device industry.
āļĄāļļāļĄāļĄāļ­āļ‡ 343 āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
LTR 52: The key to success as a risk practitioner in the medical device industry.
Collaborate for success in risk management
āļĄāļļāļĄāļĄāļ­āļ‡ 323 āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
Collaborate for success in risk management
LTR 50: Humility is the key to startup success
āļĄāļļāļĄāļĄāļ­āļ‡ 284 āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
LTR 50: Humility is the key to startup success
RM roundup #3: 10 noteworthy risk-related LinkedIn posts
āļĄāļļāļĄāļĄāļ­āļ‡ 284 āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
RM roundup #3: 10 noteworthy risk-related LinkedIn posts
Webinar: FDA warning letter case study
āļĄāļļāļĄāļĄāļ­āļ‡ 894 āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
Webinar: FDA warning letter case study
LTR 49: A clinician's view on AI/ML enabled medical devices
āļĄāļļāļĄāļĄāļ­āļ‡ 474 āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
LTR 49: A clinician's view on AI/ML enabled medical devices
LTR 48: Integrating purchasing controls across product lifecycle
āļĄāļļāļĄāļĄāļ­āļ‡ 325 āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
LTR 48: Integrating purchasing controls across product lifecycle
Webinar: How to create a master harms list using standard codes
āļĄāļļāļĄāļĄāļ­āļ‡ 1105 āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
Webinar: How to create a master harms list using standard codes
LTR 46: Tips to boost effectiveness of medical device post-market surveillance
āļĄāļļāļĄāļĄāļ­āļ‡ 525 āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
LTR 46: Tips to boost effectiveness of medical device post-market surveillance
LTR Weekly Digest #31 - 6th April, 2024
āļĄāļļāļĄāļĄāļ­āļ‡ 235 āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
LTR Weekly Digest #31 - 6th April, 2024
LTR 45: A patient's perspective on CGMs
āļĄāļļāļĄāļĄāļ­āļ‡ 235 āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
LTR 45: A patient's perspective on CGMs
LTR 44: Why we need a new approach to learning medical software and medical AI
āļĄāļļāļĄāļĄāļ­āļ‡ 376 āļŦāļĨāļēāļĒāđ€āļ”āļ·āļ­āļ™āļāđˆāļ­āļ™
LTR 44: Why we need a new approach to learning medical software and medical AI